Novartis/Amgen’s migraine drug excites with phase 3 data
Amgen, migraine, Novartis, Teva
0 Comment
Erenumab under review in US and EU
Teva
New Teva CEO axes R&D chief Hayden in boardroom shakeup
Allergan, generics, jobs, R&D, Teva
0 Comment
R&D chief Michael Hayden to leave at year end.
Huntington’s Disease wearable gets backing from NIH
BioSensics, digital health, Huntington's disease, Teva, wearables
0 Comment
BioSensics’ HDWear provides real-time motor function scores in Huntington’s patients.
Teva appoints Lundbeck’s Kare Schultz as CEO
jobs, multiple sclerosis, Novo Nordisk, Teva
0 Comment
Unlike AZ’s Soriot, Schultz “couldn’t refuse” top job at Teva.
Bidders lining up for Teva women’s health unit
Allergan generics buyout left Teva with $35m debts
AZ CEO set to take charge at Teva – report
AstraZeneca, cancer, jobs, Teva
0 Comment
Report raises concerns about outcome of MYSTIC trial.
Teva files orphan blockbuster hope in tardive dyskinesia
Huntington's disease, neurology, orphan, Rare diseases, tardive dyskinesia, Teva
0 Comment
SD-809 will be vital for Teva if approved.
Orphan drugs will fuel pharma’s future – and a pricing pushback too
cancer, CAR T, Celgene, EURORDIS, immunotherapy, Kite, Novartis, orphan drugs, Rare diseases, Shire, Teva
0 Comment
Evaluate predicts sales could approach $8bn if approved.
Mylan settles narcolepsy drug pay-for-delay case
generic, litigation, Mylan, neurology, pay-for-delay, Teva
0 Comment
Payment ends decade of litigation.